Geras pasirinkimas - Company finances
|
EUR
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 7,991 | 24,931 |
| Profit before tax | 4,184 | 16,031 |
| Net profit | 3,975 | 15,229 |
| Equity | 709 | 17,060 |
| Liabilities | 6,451 | 2,211 |
| Non-current assets | 0 | 0 |
| Current assets | 7,160 | 19,271 |
| Total assets | 7,160 | 19,271 |
|
Taxes paid
|
||
| STI taxes | 991 | 564 |
|
Financial indicators
|
||
| Revenue change y/y | - | +212.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 55.5% | 79.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 560.6% | 89.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 49.7% | 61.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 52.4% | 64.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 9.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Geras pasirinkimas - Social security debts
The company had no debts to Sodra
Geras pasirinkimas - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-02-01 | 2026-02-01 | 147.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Geras pasirinkimas, MB (code 306633617) is a Lithuanian small partnership operating in retail sale of pharmaceutical products. In the latest financial year, 2025, the company generated revenue of EUR 24.9K and net profit of EUR 15.2K, with a profit margin of 61.1%. Revenue increased by 212.0% year on year from EUR 8.0K in 2024, while net profit rose from EUR 4.0K to EUR 15.2K over the same period. The 2024–2025 trajectory shows a strong expansion in both sales and profitability. Balance sheet figures at the end of 2025 show total assets of EUR 19.3K, equity of EUR 17.1K and liabilities of EUR 2.2K, indicating a highly equity-funded structure. Key ratios for 2025 were strong, with return on equity at 89.3%, return on assets at 79.0%, debt-to-equity at 0.13 and asset turnover at 1.29x. The company’s short-term assets also matched total assets at EUR 19.3K, supporting a liquid balance sheet position.